{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T23:32:14Z","timestamp":1768087934438,"version":"3.49.0"},"reference-count":78,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2010,2,2]],"date-time":"2010-02-02T00:00:00Z","timestamp":1265068800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2010,2,2]],"date-time":"2010-02-02T00:00:00Z","timestamp":1265068800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Rheumatol"],"published-print":{"date-parts":[[2010,3]]},"DOI":"10.1038\/nrrheum.2010.2","type":"journal-article","created":{"date-parts":[[2010,2,2]],"date-time":"2010-02-02T10:01:47Z","timestamp":1265104907000},"page":"129-137","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":143,"title":["Immunotherapy of myositis: issues, concerns and future prospects"],"prefix":"10.1038","volume":"6","author":[{"given":"Marinos C.","family":"Dalakas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,2,2]]},"reference":[{"key":"BFnrrheum20102_CR1","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1056\/NEJM199111213252107","volume":"325","author":"MC Dalakas","year":"1991","unstructured":"Dalakas, M. C. Polymyositis, dermatomyositis and inclusion-body myositis. N. Engl. J. Med. 325, 1487\u20131498 (1991).","journal-title":"N. Engl. J. Med."},{"key":"BFnrrheum20102_CR2","first-page":"1321","volume-title":"Myology","author":"AG Engel","year":"2004","unstructured":"Engel, A. G. & Hohlfeld, R. in Myology 3rd edn (eds Engel, A. G. & Franzini-Armstrong, C.) 1321\u20131366 (McGraw-Hill, New York, 2004)."},{"key":"BFnrrheum20102_CR3","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1016\/S0889-857X(02)00021-2","volume":"28","author":"FL Mastaglia","year":"2002","unstructured":"Mastaglia, F. L. & Phillips, B. A. Idiopathic inflammatory myopathies: epidemiology, classification and diagnostic criteria. Rheum. Dis. Clin. North Am. 28, 723\u2013741 (2002).","journal-title":"Rheum. Dis. Clin. North Am."},{"key":"BFnrrheum20102_CR4","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/S0140-6736(03)14368-1","volume":"362","author":"MC Dalakas","year":"2003","unstructured":"Dalakas, M. C. & Hohlfeld, R. Polymyositis and dermatomyositis. Lancet 362, 971\u2013982 (2003).","journal-title":"Lancet"},{"key":"BFnrrheum20102_CR5","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1097\/00019052-200410000-00006","volume":"17","author":"MC Dalakas","year":"2004","unstructured":"Dalakas, M. C. Inflammatory disorders of muscle: progress in polymyositis, dermatomyositis and inclusion body myositis. Curr. Opin. Neurol. 17, 561\u2013567 (2004).","journal-title":"Curr. Opin. Neurol."},{"key":"BFnrrheum20102_CR6","doi-asserted-by":"publisher","first-page":"2704","DOI":"10.3899\/jrheum.090549","volume":"36","author":"BB Antiochos","year":"2009","unstructured":"Antiochos, B. B.  et al. Malignancy is associated with dermatomyositis but not polymyositis in Northern New England, USA. J. Rheumatol. 36, 2704\u20132710 (2009).","journal-title":"J. Rheumatol."},{"key":"BFnrrheum20102_CR7","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1055\/s-2008-1041132","volume":"13","author":"EA Sekul","year":"1993","unstructured":"Sekul, E. A. & Dalakas, M. C. Inclusion body myositis: new concepts. Semin. Neurol. 13, 256\u2013263 (1993).","journal-title":"Semin. Neurol."},{"key":"BFnrrheum20102_CR8","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1016\/S1474-4422(07)70171-0","volume":"6","author":"M Needham","year":"2007","unstructured":"Needham, M. & Mastaglia, F. L. Inclusion body myositis: current pathogenetic concepts and diagnostic and therapeutic approaches. Lancet Neurol. 6, 620\u2013631 (2007).","journal-title":"Lancet Neurol."},{"key":"BFnrrheum20102_CR9","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.nmd.2007.11.001","volume":"18","author":"M Needham","year":"2008","unstructured":"Needham, M. & Mastaglia, F. L. Sporadic inclusion body myositis: a continuing puzzle. Neuromuscul. Disord. 18, 6\u201316 (2008).","journal-title":"Neuromuscul. Disord."},{"key":"BFnrrheum20102_CR10","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1002\/ana.410380504","volume":"38","author":"RC Griggs","year":"1995","unstructured":"Griggs, R. C.  et al. Inclusion body myositis and myopathies. Ann. Neurol. 38, 705\u2013713 (1995).","journal-title":"Ann. Neurol."},{"key":"BFnrrheum20102_CR11","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1002\/ana.20464","volume":"57","author":"SA Greenberg","year":"2005","unstructured":"Greenberg, S. A.  et al. Interferon-\u03b1\/\u03b2-mediated innate immune mechanisms in dermatomyositis. Ann. Neurol. 57, 664\u2013678 (2005).","journal-title":"Ann. Neurol."},{"key":"BFnrrheum20102_CR12","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1097\/00002281-199811000-00005","volume":"10","author":"V Askanas","year":"1998","unstructured":"Askanas, V. & Engel, W. K. Sporadic inclusion-body myositis and hereditary inclusion-body myopathies: current concepts of diagnosis and pathogenesis. Curr. Opin. Rheumatol. 10, 530\u2013542 (1998).","journal-title":"Curr. Opin. Rheumatol."},{"key":"BFnrrheum20102_CR13","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1001\/archneur.1991.00530240033013","volume":"48","author":"JR Mendel","year":"1991","unstructured":"Mendel, J. R., Sahenk, Z., Gales, L. & Paul, L. Amyloid filaments in inclusion body myositis. Novel findings provide insight into nature of filaments. Arch. Neurol. 48, 1229\u20131234 (1991).","journal-title":"Arch. Neurol."},{"key":"BFnrrheum20102_CR14","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1038\/ncpneuro0261","volume":"2","author":"MC Dalakas","year":"2006","unstructured":"Dalakas, M. C. Sporadic inclusion body myositis: diagnosis, pathogenesis and therapeutic strategies. Nat. Clin. Prac. Neurol. 2, 437\u2013447 (2006).","journal-title":"Nat. Clin. Prac. Neurol."},{"key":"BFnrrheum20102_CR15","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1136\/jnnp.2008.168294","volume":"80","author":"MC Dalakas","year":"2009","unstructured":"Dalakas, M. C. Toxic and drug-induced myopathies. J. Neurol. Neurosurg. Psych. 80, 832\u2013838 (2009).","journal-title":"J. Neurol. Neurosurg. Psych."},{"key":"BFnrrheum20102_CR16","first-page":"527","volume":"2","author":"G Karpati","year":"1993","unstructured":"Karpati, G. & Carpenter, S. Pathology of the inflammatory myopathies. Bailli\u00e8re's Clin. Neurol. 2, 527\u2013556 (1993).","journal-title":"Bailli\u00e8re's Clin. Neurol."},{"key":"BFnrrheum20102_CR17","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/0046-8177(89)90128-7","volume":"20","author":"AM Emslie-Smith","year":"1989","unstructured":"Emslie-Smith, A. M., Arahata, K. & Engel, A. G. Major histocompatibility complex class I antigen expression, immunologicalization of interferon subtypes, and T cell-mediated cytotoxicity in myopathies. Hum. Pathol. 20, 224\u2013231 (1989).","journal-title":"Hum. Pathol."},{"key":"BFnrrheum20102_CR18","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1002\/ana.410230111","volume":"23","author":"G Karpati","year":"1988","unstructured":"Karpati, G., Pouliot, Y. & Carpenter, S. Expression of immunoreactive major histocompatability complex products in human skeletal muscles. Ann. Neurol. 23, 64\u201372 (1988).","journal-title":"Ann. Neurol."},{"key":"BFnrrheum20102_CR19","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1212\/01.wnl.0000277527.69388.fe","volume":"70","author":"N Chahin","year":"2008","unstructured":"Chahin, N. & Engel, A. G. Correlation of muscle biopsy, clinical course, and outcome in PM and sporadic IBM. Neurology 70, 418\u2013424 (2008).","journal-title":"Neurology"},{"key":"BFnrrheum20102_CR20","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1093\/brain\/120.1.39","volume":"120","author":"G Blume","year":"1997","unstructured":"Blume, G., Pestronk, A., Frank, B. & Johns, D. R. Polymyositis with cytochrome oxidase negative muscle fibres. Early quadriceps weakness and poor response to immunosuppressive therapy. Brain 120, 39\u201345 (1997).","journal-title":"Brain"},{"key":"BFnrrheum20102_CR21","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1055\/s-2003-41136","volume":"23","author":"MC Dalakas","year":"2003","unstructured":"Dalakas, M. C. Therapeutic approaches in patients with inflammatory myopathies. Semin. Neurol. 23, 199\u2013206 (2003).","journal-title":"Semin. Neurol."},{"key":"BFnrrheum20102_CR22","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1056\/NEJM199205213262102","volume":"326","author":"FW Miller","year":"1992","unstructured":"Miller, F. W.  et al. Controlled trial of plasma exchange and leukopheresis in patients with polymyositis and dermatomyositis. N. Engl. J. Med. 326, 1380\u20131384 (1992).","journal-title":"N. Engl. J. Med."},{"key":"BFnrrheum20102_CR23","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1056\/NEJM198602063140601","volume":"314","author":"JT Kissel","year":"1986","unstructured":"Kissel, J. T., Mendell, J. R. & Rammohan, K. W. Microvascular deposition of complement membrane attack complex in dermatomyositis. N. Engl. J. Med. 314, 329\u2013334 (1986).","journal-title":"N. Engl. J. Med."},{"key":"BFnrrheum20102_CR24","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1002\/ana.410270402","volume":"27","author":"AM Emslie-Smith","year":"1990","unstructured":"Emslie-Smith, A. M. & Engel, A. G. Microvascular changes in early and advanced dermatomyositis: a quantitative study. Ann. Neurol. 27, 343\u2013356 (1990).","journal-title":"Ann. Neurol."},{"issue":"Suppl. 1","key":"BFnrrheum20102_CR25","doi-asserted-by":"publisher","first-page":"S74","DOI":"10.1002\/ana.410370709","volume":"37","author":"MC Dalakas","year":"1995","unstructured":"Dalakas, M. C. Immunopathogenesis of inflammatory myopathies. Ann. Neurol. 37 (Suppl. 1), S74\u2013S86 (1995).","journal-title":"Ann. Neurol."},{"key":"BFnrrheum20102_CR26","doi-asserted-by":"publisher","first-page":"1658","DOI":"10.1002\/art.22558","volume":"56","author":"CM L\u00f3pez de Padilla","year":"2007","unstructured":"L\u00f3pez de Padilla, C. M.  et al. Plasmacytoid dendritic cells in inflamed muscles of patients with juvenile dermatomyositis. Arthritis Rheum. 56, 1658\u20131668 (2007).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum20102_CR27","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/0165-5728(95)00045-4","volume":"59","author":"DS Tews","year":"1995","unstructured":"Tews, D. S. & Goebel, H. H. Expression of cell adhesion molecules in inflammatory myopathies. J. Neuroimmunol. 59, 185\u2013194 (1995).","journal-title":"Neuroimmunol."},{"key":"BFnrrheum20102_CR28","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1097\/00005072-199407000-00008","volume":"53","author":"JL De Bleecker","year":"1994","unstructured":"De Bleecker, J. L. & Engel, A. G. Expression of cell adhesion molecules in inflammatory myopathies and Duchenne dystrophy. J. Neuropathol. Exp. Neurol. 53, 369\u2013376 (1994).","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"BFnrrheum20102_CR29","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1212\/WNL.58.12.1779","volume":"58","author":"JL De Bleecker","year":"2002","unstructured":"De Bleecker, J. L., De Paepe, B., Vanwalleghem, I. E. & Schr\u00f6der, J. M. Differential expression of chemokines in inflammatory myopathies. Neurology 58, 1779\u20131785 (2002).","journal-title":"Neurology"},{"key":"BFnrrheum20102_CR30","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1111\/j.1365-2990.2004.00591.x","volume":"31","author":"M Civatte","year":"2005","unstructured":"Civatte, M.  et al. Expression of the beta chemokines CCL3, CCL4, CCL5 and their receptors in idiopathic inflammatory myopathies. Neuropathol. Appl. Neurobiol. 31, 70\u201379 (2005).","journal-title":"Neuropathol. Appl. Neurobiol."},{"key":"BFnrrheum20102_CR31","first-page":"81","volume":"151","author":"I Illa","year":"1997","unstructured":"Illa, I.  et al. Signal transducer and activator of transcription 1 in human muscle: implications in inflammatory myopathies. Am. J. Pathol. 151, 81\u201388 (1997).","journal-title":"Am. J. Pathol."},{"key":"BFnrrheum20102_CR32","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1038\/ncprheum0140","volume":"2","author":"MC Dalakas","year":"2006","unstructured":"Dalakas, M. C. Mechanisms of disease: signaling pathways and immunobiology of inflammatory myopathies. Nat. Clin. Pract. Rheumatol. 2, 219\u2013227 (2006).","journal-title":"Nat. Clin. Pract. Rheumatol."},{"key":"BFnrrheum20102_CR33","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1002\/ana.410160206","volume":"16","author":"K Arahata","year":"1984","unstructured":"Arahata, K. & Engel, A. G. Monoclonal antibody analysis of mononuclear cells in myopathies. I: Quantitation of subsets according to diagnosis and sites of accumulation and demonstration and counts of muscle fibers invaded by T cells. Ann. Neurol. 16, 193\u2013208 (1984).","journal-title":"Ann. Neurol."},{"key":"BFnrrheum20102_CR34","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1002\/ana.410190203","volume":"19","author":"K Arahata","year":"1986","unstructured":"Arahata, K. & Engel, A. G. Monoclonal antibody analysis of mononuclear cells in myopathies III Immunoelectron microscopy aspects of cell-mediated muscle fibre injury. Ann. Neurol. 19, 112\u2013125 (1986).","journal-title":"Ann. Neurol."},{"key":"BFnrrheum20102_CR35","doi-asserted-by":"publisher","first-page":"2905","DOI":"10.1172\/JCI118749","volume":"97","author":"N Goebel","year":"1996","unstructured":"Goebel, N.  et al. Differential expression of perforin in muscle-infiltrating T cells in polymyositis and dermatomyositis. J. Clin. Invest. 97, 2905\u20132910 (1996).","journal-title":"J. Clin. Invest."},{"key":"BFnrrheum20102_CR36","doi-asserted-by":"publisher","first-page":"1863","DOI":"10.1084\/jem.181.5.1863","volume":"181","author":"A Bender","year":"1995","unstructured":"Bender, A.  et al. T cell receptor repertoire in polymyositis: clonal expansion of autoaggressive CD8+ T cells. J. Exp. Med. 181, 1863\u20131868 (1995).","journal-title":"J. Exp. Med."},{"key":"BFnrrheum20102_CR37","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1016\/S0046-8177(86)80180-0","volume":"17","author":"AG Engel","year":"1986","unstructured":"Engel, A. G. & Arahata, K. Mononuclear cells in myopathies: quantitation of functionally distinct subsets, recognition of antigen-specific cell-mediated cytotoxicity in some diseases, and implications for the pathogenesis of the different inflammatory myopathies. Hum. Pathol. 17, 704\u2013721 (1986).","journal-title":"Hum. Pathol."},{"key":"BFnrrheum20102_CR38","doi-asserted-by":"publisher","first-page":"2030","DOI":"10.1093\/brain\/123.10.2030","volume":"123","author":"K Amemiya","year":"2000","unstructured":"Amemiya, K., Granger, R. P. & Dalakas, M. C. Clonal restriction of T-cell receptor expression by infiltrating lymphocytes in inclusion body myositis persists over time. Studies in repeated muscle biopsies. Brain 123, 2030\u20132039 (2000).","journal-title":"Brain"},{"key":"BFnrrheum20102_CR39","doi-asserted-by":"publisher","first-page":"4090","DOI":"10.1073\/pnas.0236183100","volume":"100","author":"M Hofbauer","year":"2003","unstructured":"Hofbauer, M.  et al. Clonal tracking of autoaggressive T cells in polymyositis by combining laser microdissection, single-cell PCR, and CDR3-spectratype analysis. Proc. Natl Acad. Sci. USA 100, 4090\u20134095 (2003).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrrheum20102_CR40","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1093\/brain\/awg114","volume":"126","author":"H Wiendl","year":"2003","unstructured":"Wiendl, H.  et al. Muscle fibres and cultured muscle cells express the B7.1\/2-related inducible co-stimulatory molecule, ICOSL: implications for the pathogenesis of inflammatory myopathies. Brain 126, 1026\u20131035 (2003).","journal-title":"Brain"},{"key":"BFnrrheum20102_CR41","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.it.2005.05.003","volume":"26","author":"H Wiendl","year":"2005","unstructured":"Wiendl, H., Hohlfeld, R. & Kieseier, B. C. Immunobiology of muscle: advances in understanding an immunological microenvironment. Trends Immunol. 26, 373\u2013380 (2005).","journal-title":"Trends Immunol."},{"key":"BFnrrheum20102_CR42","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1093\/brain\/awh148","volume":"127","author":"J Schmidt","year":"2004","unstructured":"Schmidt, J., Rakocevic, G., Raju, R. & Dalakas, M. C. Upregulated inducible co-stimulator (ICOS) and ICOS-ligand in inclusion body myositis muscle: significance for CD8+ T cell cytotoxicity. Brain 127, 1182\u20131190 (2004).","journal-title":"Brain"},{"key":"BFnrrheum20102_CR43","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1093\/brain\/awn053","volume":"131","author":"J Schmidt","year":"2008","unstructured":"Schmidt, J.  et al. Interrelation of inflammation and APP in sIBM: IL-1\u03b2 induces accumulation of \u03b2-amyloid in skeletal muscle. Brain 131, 1228\u20131240 (2008).","journal-title":"Brain"},{"key":"BFnrrheum20102_CR44","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1007\/s11926-008-0053-2","volume":"10","author":"IN Targoff","year":"2008","unstructured":"Targoff, I. N. Autoantibodies and their significance in myositis. Curr. Rheumatol. Rep. 10, 333\u2013340 (2008).","journal-title":"Curr. Rheumatol. Rep."},{"key":"BFnrrheum20102_CR45","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.nmd.2005.12.008","volume":"16","author":"MC Dalakas","year":"2006","unstructured":"Dalakas, M. C. Therapeutic targets in patients with inflammatory myopathies: present approaches and a look to the future. Neuromuscul. Disord. 16, 223\u2013236 (2006).","journal-title":"Neuromuscul. Disord."},{"key":"BFnrrheum20102_CR46","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1002\/art.1780240107","volume":"24","author":"TW Bunch","year":"1981","unstructured":"Bunch, T. W. Prednisone and azathioprine for polymyositis: long-term followup. Arthritis Rheum. 24, 45\u201348 (1981).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum20102_CR47","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1002\/(SICI)1097-4598(199706)20:6<651::AID-MUS1>3.0.CO;2-7","volume":"20","author":"FL Mastaglia","year":"1997","unstructured":"Mastaglia, F. L., Phillips, B. A. & Zilko, P. Treatment of inflammatory myopathies. Muscle Nerve 20, 651\u2013664 (1997).","journal-title":"Muscle Nerve"},{"key":"BFnrrheum20102_CR48","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1097\/00002281-199411000-00008","volume":"6","author":"MC Dalakas","year":"1994","unstructured":"Dalakas, M. C. Current treatment of the inflammatory myopathies. Curr. Opin. Rheumatol. 6, 595\u2013601 (1994).","journal-title":"Curr. Opin. Rheumatol."},{"key":"BFnrrheum20102_CR49","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1056\/NEJM199312303292704","volume":"329","author":"MC Dalakas","year":"1993","unstructured":"Dalakas, M. C.  et al. A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N. Engl. J. Med. 329, 1993\u20132000 (1993).","journal-title":"N. Engl. J. Med."},{"key":"BFnrrheum20102_CR50","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1136\/jnnp.65.1.107","volume":"65","author":"FL Mastaglia","year":"1998","unstructured":"Mastaglia, F. L., Phillips, B. A. & Zilko, P. J. Immunoglobulin therapy in inflammatory myopathies. J. Neurol. Neurosurg. Psychiatry 65, 107\u2013110 (1998).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"Spec. No. 2","key":"BFnrrheum20102_CR51","first-page":"9","volume":"29","author":"P Ch\u00e9rin","year":"2008","unstructured":"Ch\u00e9rin, P. Current therapy for polymyositis and dermatomyositis [French]. Rev. Med. Interne. 29 (Spec. No. 2), 9\u201314 (2008).","journal-title":"Rev. Med. Interne."},{"key":"BFnrrheum20102_CR52","doi-asserted-by":"publisher","first-page":"2367","DOI":"10.1001\/jama.291.19.2367","volume":"291","author":"MC Dalakas","year":"2004","unstructured":"Dalakas, M. C. Intravenous immunoglobulin in autoimmune neuromuscular diseases. JAMA 291, 2367\u20132375 (2004).","journal-title":"JAMA"},{"key":"BFnrrheum20102_CR53","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1038\/ncpneuro0901","volume":"4","author":"MC Dalakas","year":"2008","unstructured":"Dalakas, M. C. B cells as therapeutic targets in autoimmune neurological disorders. Nat. Clin. Pract. Neurol. 4, 557\u2013567 (2008).","journal-title":"Nat. Clin. Pract. Neurol."},{"key":"BFnrrheum20102_CR54","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1002\/art.20849","volume":"52","author":"TD Levine","year":"2005","unstructured":"Levine, T. D. Rituximab in the treatment of dermatomyositis: an open-label pilot study. Arthritis Rheum. 52, 601\u2013607 (2005).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum20102_CR55","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1001\/archderm.143.6.763","volume":"143","author":"L Chung","year":"2007","unstructured":"Chung, L., Genovese, M. C. & Fiorentino, D. F. A pilot trial of rituximab in the treatment of patients with dermatomyositis. Arch. Dermatol. 143, 763\u2013767 (2007).","journal-title":"Arch. Dermatol."},{"key":"BFnrrheum20102_CR56","doi-asserted-by":"publisher","first-page":"1744","DOI":"10.1016\/j.transproceed.2007.11.072","volume":"40","author":"Z Kaposztas","year":"2008","unstructured":"Kaposztas, Z., Etheridge, W. B. & Kahan, B. D. Case report: successful treatment of posttransplant lymphoproliferative disorder and quiescence of dermatomyositis with rituximab and sirolimus. Transplant. Proc. 40, 1744\u20131746 (2008).","journal-title":"Transplant. Proc."},{"key":"BFnrrheum20102_CR57","doi-asserted-by":"publisher","first-page":"1762","DOI":"10.1016\/S0140-6736(99)01927-3","volume":"353","author":"CV Oddis","year":"1999","unstructured":"Oddis, C. V., Sciurba, F. C., Elmagd, K. A. & Starzl, T. E. Tacrolimus in refractory polymyositis with interstitial lung disease. Lancet 353, 1762\u20131763 (1999).","journal-title":"Lancet"},{"key":"BFnrrheum20102_CR58","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1007\/s10067-004-0865-z","volume":"23","author":"Y Shimojima","year":"2004","unstructured":"Shimojima, Y.  et al. Efficacy of tacrolimus in treatment of polymyositis associated with myasthenia gravis. Clin. Rheumatol. 23, 262\u2013265 (2004).","journal-title":"Clin. Rheumatol."},{"key":"BFnrrheum20102_CR59","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1007\/s00431-004-1497-7","volume":"163","author":"A Yamada","year":"2004","unstructured":"Yamada, A., Ohshima, Y., Omata, N., Yasutomi, M. & Mayumi, M. Steroid-sparing effect of tacrolimus in a patient with juvenile dermatomyositis presenting poor bioavailability of cyclosporine A. Eur. J. Pediatr. 163, 561\u2013562 (2004).","journal-title":"Eur. J. Pediatr."},{"key":"BFnrrheum20102_CR60","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1055\/s-2003-41139","volume":"23","author":"R Hohlfeld","year":"2003","unstructured":"Hohlfeld, R. & Dalakas, M. C. Basic principles of immunotherapy for neurologic diseases. Semin. Neurol. 23, 121\u2013132 (2003).","journal-title":"Semin. Neurol."},{"key":"BFnrrheum20102_CR61","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1016\/j.nurt.2008.08.008","volume":"5","author":"H Wiendl","year":"2008","unstructured":"Wiendl, H. Idiopathic inflammatory myopathies: current and future therapeutic options. Neurotherapeutics 5, 548\u2013557 (2008).","journal-title":"Neurotherapeutics"},{"key":"BFnrrheum20102_CR62","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1159\/000070852","volume":"50","author":"GJ Hengstman","year":"2003","unstructured":"Hengstman, G. J.  et al. Successful treatment of dermatomyositis and polymyositis with anti-tumor necrosis-factor-alpha: preliminary observations. Eur. Neurol. 50, 10\u201315 (2003).","journal-title":"Eur. Neurol."},{"key":"BFnrrheum20102_CR63","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1093\/rheumatology\/keh079","volume":"43","author":"I Labioche","year":"2004","unstructured":"Labioche, I.  et al. Refractory polymyositis responding to infliximab: extended follow-up. Rheumatology (Oxford) 43, 531\u2013532 (2004).","journal-title":"Rheumatology (Oxford)"},{"key":"BFnrrheum20102_CR64","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1159\/000079547","volume":"52","author":"GJ Hengstman","year":"2004","unstructured":"Hengstman, G. J., van den Hoogen, F. H. & van Engelen, B. G. Treatment of dermatomyositis and polymyositis with anti-tumor necrosis factor-alpha: long-term follow-up. Eur. Neurol. 52, 61\u201363 (2004).","journal-title":"Eur. Neurol."},{"key":"BFnrrheum20102_CR65","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1136\/ard.2007.077974","volume":"67","author":"M Dastmalchi","year":"2008","unstructured":"Dastmalchi, M.  et al. A high incidence of disease flares in an open pilot study of infliximab in patients with refractory polymyositis. Ann. Rheum. Dis. 67, 1670\u20131677 (2008).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum20102_CR66","unstructured":"US Food and Drug Administration. FDA public health advisory: updated safety information about Raptiva (efalizumab) [http:\/\/www.fda.gov\/Drugs\/DrugSafety\/PublicHealthAdvisories\/ucm110605.htm] (2009)."},{"key":"BFnrrheum20102_CR67","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1212\/01.wnl.0000267662.41734.1f","volume":"69","author":"JW Rose","year":"2007","unstructured":"Rose, J. W.  et al. Daclizumab phase II trial in relapsing and remitting multiple sclerosis: MRI and clinical results. Neurology 69, 785\u2013789 (2007).","journal-title":"Neurology"},{"key":"BFnrrheum20102_CR68","first-page":"2080","volume":"35","author":"B Thomson","year":"2008","unstructured":"Thomson, B.  et al. Alemtuzumab (Campath-1H) for treatment of refractory polymyositis. J. Rheumatol. 35, 2080\u20132082 (2008).","journal-title":"J. Rheumatol."},{"key":"BFnrrheum20102_CR69","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1212\/01.wnl.0000338569.32367.3d","volume":"72","author":"P O'Connor","year":"2009","unstructured":"O'Connor, P.  et al. Oral fingolimod (FTY720) in multiple sclerosis: two-year results of a phase II extension study. Neurology 72, 73\u201379 (2009).","journal-title":"Neurology"},{"key":"BFnrrheum20102_CR70","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1172\/JCI117520","volume":"94","author":"M Basta","year":"1994","unstructured":"Basta, M. & Dalakas, M. C. High-dose intravenous immunoglobulin exerts its beneficial effect in patients with dermatomyositis by blocking endomysial deposition of activated complement fragments. J. Clin. Invest. 94, 1729\u20131735 (1994).","journal-title":"J. Clin. Invest."},{"key":"BFnrrheum20102_CR71","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/ana.21452","volume":"64","author":"MC Dalakas","year":"2008","unstructured":"Dalakas, M. C. Interplay between inflammation and degeneration: using inclusion body myositis to study \u201cneuroinflammation\u201d. Ann. Neurol. 64, 1\u20133 (2008).","journal-title":"Ann. Neurol."},{"key":"BFnrrheum20102_CR72","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/S0022-510X(01)00478-6","volume":"185","author":"N Mowzoon","year":"2001","unstructured":"Mowzoon, N., Sussman, A. & Bradley, W. G. Mycophenolate (CellCept) treatment of myasthenia gravis, chronic inflammatory polyneuropathy and inclusion body myositis. J. Neurol. Sci. 185, 119\u2013122 (2001).","journal-title":"J. Neurol. Sci."},{"key":"BFnrrheum20102_CR73","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1212\/WNL.48.3.712","volume":"48","author":"MC Dalakas","year":"1997","unstructured":"Dalakas, M. C.  et al. Treatment of inclusion body myositis with IVIg: a double-blind, placebo-control study. Neurology 48, 712\u2013716 (1997).","journal-title":"Neurology"},{"key":"BFnrrheum20102_CR74","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1007\/s004150050005","volume":"247","author":"MC Walter","year":"2000","unstructured":"Walter, M. C.  et al. High-dose immunoglobulin therapy in sporadic inclusion body myositis: a double-blind, placebo-controlled study. J. Neurol. 247, 22\u201328 (2000).","journal-title":"J. Neurol."},{"key":"BFnrrheum20102_CR75","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1212\/WNL.58.2.326","volume":"58","author":"P Cherin","year":"2002","unstructured":"Cherin, P.  et al. Intravenous immunoglobulin for dysphagia of inclusion body myositis. Neurology 58, 326 (2002).","journal-title":"Neurology"},{"key":"BFnrrheum20102_CR76","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1093\/brain\/awp104","volume":"132","author":"MC Dalakas","year":"2009","unstructured":"Dalakas, M. C.  et al. Effect of alemtuzumab (CAMPATH 1-H) in patients with inclusion body myositis. Brain 132, 1536\u20131544 (2009).","journal-title":"Brain"},{"key":"BFnrrheum20102_CR77","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1002\/mus.880140514","volume":"14","author":"A Verma","year":"1991","unstructured":"Verma, A., Bradley, W., Adesina, A. M., Sofferman, R. & Pendlebury, W. W. Inclusion body myositis with cricopharyngeus muscle involvement and severe dysphagia. Muscle Nerve 14, 470\u2013473 (1991).","journal-title":"Muscle Nerve"},{"key":"BFnrrheum20102_CR78","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1002\/(SICI)1097-4598(199710)20:10<1242::AID-MUS6>3.0.CO;2-C","volume":"20","author":"SA Spector","year":"1997","unstructured":"Spector, S. A.  et al. Safety and efficacy of strength training in patients with sporadic inclusion body myositis. Muscle Nerve 20, 1242\u20131248 (1997).","journal-title":"Muscle Nerve"}],"container-title":["Nature Reviews Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/nrrheum.2010.2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/nrrheum.2010.2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/nrrheum.2010.2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,30]],"date-time":"2022-07-30T09:05:11Z","timestamp":1659171911000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrrheum.2010.2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,2,2]]},"references-count":78,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2010,3]]}},"alternative-id":["BFnrrheum20102"],"URL":"https:\/\/doi.org\/10.1038\/nrrheum.2010.2","relation":{},"ISSN":["1759-4790","1759-4804"],"issn-type":[{"value":"1759-4790","type":"print"},{"value":"1759-4804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,2,2]]},"assertion":[{"value":"2 February 2010","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The author has acted as a consultant for and has received honoraria from Baxter Healthcare, Octapharma and Talecris Biotherapeutics. The Journal Editor J. Buckland and the CME question author C. P. Vega declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}